SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of May 2017
Commission File Number 001-38068
Zymeworks Inc.
(Translation of registrant’s name into English)
Suite 540, 1385 West 8th Avenue, Vancouver, British Columbia, Canada, V6H 3V9
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
EXHIBITS INCLUDED AS PART OF THIS REPORT
Exhibit
| 99.1 |
Press Release – Zymeworks Thanks Resigning Directors For Their Service
|
| 99.2 |
Press Release – Zymeworks to Host First Quarter 2017 Financial Results Conference Call on May 15, 2017
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
ZYMEWORKS INC.
|
|||
|
|
(Registrant)
|
|||
|
|
|
|||
|
Date: May 10, 2017
|
|
By:
|
|
/S/ Neil Klompas
|
|
|
|
Name:
Title:
|
|
Neil Klompas
Chief Financial Officer
|
Exhibit 99.1
Zymeworks Thanks Resigning Directors For Their Service
Vancouver, Canada (May 9, 2017) – Zymeworks Inc. (“Zymeworks”) (NYSE: ZYME; TSX: ZYME) a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, wishes to publically acknowledge the contributions of the following directors who resigned from the Company’s board of director upon the completion of its initial public offering: Ms. Shermaine Tilley, Mr. Dion Madsen, and Mr. Kerry Blanchard.
“We would like to thank Shermaine, Dion, and Kerry for their years of invaluable service,” said Ali Tehrani, Ph.D., Zymeworks’ President & CEO. “Their insights have helped shape the company that Zymeworks is today, and each of their contributions will be felt for years to come. We wish them the best of luck in their future endeavours.”
Following the Company’s initial public offering, its board of directors is comprised of: Nick Bedford (Chair), Noel Hall, Kenneth Hillan, Hollings Renton, Ali Tehrani and Lota Zoth.
About Zymeworks
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. Zymeworks’ suite of complementary therapeutic platforms and its fully-integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly-differentiated product candidates. Zymeworks’ lead product candidate, ZW25, is a novel bispecific antibody currently being evaluated in an adaptive Phase 1 clinical trial. Zymeworks is also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. In addition to Zymeworks’ wholly-owned pipeline, its therapeutic platforms have been further leveraged through multiple strategic partnerships with global biopharmaceutical companies.
Contact:
Investor Inquiries:
David Matousek
Senior Manager, Investor Relations & Corporate Communications
(604) 678-1388
ir@zymeworks.com
Exhibit 99.2
Zymeworks to Host First Quarter 2017 Financial Results Conference Call on May 15, 2017
Vancouver, Canada, (May 9, 2017) – Zymeworks Inc. (“Zymeworks”) (NYSE:ZYME; TSX:ZYME) a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, today announces it will release first quarter 2017 financial results after the market closes on Monday, May 15, 2017. Zymeworks management will host a conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 1-800-319-4610 for North American callers, or 1-604-638-5340 for international callers. Callers should dial in five to ten minutes prior to the scheduled start time, and ask to join the Zymeworks conference call. A telephone replay of the conference call will be available by dialing 1-800-319-6413 or 1-604-638-9010 and entering access code 1440. The replay will be available after the conclusion of the conference call until May 29, 2017.
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. Zymeworks’ suite of complementary therapeutic platforms and its fully-integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly-differentiated product candidates. Zymeworks’ lead product candidate, ZW25, is a novel bispecific antibody currently being evaluated in an adaptive Phase 1 clinical trial. Zymeworks is also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. In addition to Zymeworks’ wholly-owned pipeline, its therapeutic platforms have been further leveraged through multiple strategic partnerships with global biopharmaceutical companies.
Contact:
Investor Inquiries:
David Matousek
Senior Manager, Investor Relations & Corporate Communications
(604) 678-1388
ir@zymeworks.com